High-quality recombinant protein raw materials sit at the heart of biopharmaceutical progress. At East-Mab Biomedical, we’ve built our work around products like Recombinant Human VEGF165 that hold up under the demands of advanced therapeutic development. Researchers need tools they can trust, and that’s what we aim to deliver. Our focus spans IVD, cell culture, and cell therapy, areas where material quality directly shapes outcomes.
High Purity Recombinant Human VEGF165 in Therapeutic Development
Recombinant Human Vascular Endothelial Growth Factor 165 (VEGF165) drives angiogenesis, the process by which new blood vessels form. In biopharmaceutical research, the purity and activity of recombinant protein raw materials matter enormously. High-quality VEGF165 enables accurate, reproducible experimental results, particularly when developing therapies for conditions tied to vascularization. Our products meet these standards, performing reliably across diverse applications. This supports work in regenerative medicine and oncology, where precision makes the difference.
Molecular Biology and Functional Mechanisms of VEGF165
VEGF165 is a heparin-binding homodimeric glycoprotein and a key isoform within the vascular endothelial growth factor family. It works by binding to and activating two receptor tyrosine kinases: VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 carries most of the weight when it comes to VEGF’s angiogenic and mitogenic effects on endothelial cells. Once binding occurs, a complex intracellular signaling cascade kicks off. Phosphorylation events follow, leading to cell proliferation, migration, and survival. Getting a handle on this VEGF signaling pathway matters for developing targeted therapies. Our Recombinant Human VEGF165 gives researchers a reliable tool for studying these molecular interactions with precision.
Advanced Production and Purification of Recombinant Human VEGF165
Producing high-quality recombinant proteins like Recombinant Human VEGF165 requires sophisticated methodologies. We use advanced bioreactor optimization techniques to push protein expression as high as possible. Our protein expression systems span mammalian and bacterial hosts, selected based on what each specific protein needs. Some of our recombinant proteins, like Recombinant Human IL-2, come from CHO cells to ensure proper post-translational modifications. Others, like Recombinant Human IL-1β, are produced in E. coli when high yield is the priority.
Purification runs through multi-step chromatography processes, delivering exceptional purity and biological activity. We follow stringent GMP manufacturing guidelines where applicable, which keeps product consistency and safety on track. This approach drives down impurities and endotoxin levels, both of which matter for sensitive applications. Our investment of over $30 million in R&D has built a world-class platform for recombinant protein production. The result is Recombinant Human VEGF165 that meets the highest industry standards.
Applications of Recombinant Human VEGF165 in Research and Diagnostics
Recombinant Human VEGF165 finds use across a wide range of scientific and diagnostic fields. In angiogenesis assays, it stimulates endothelial cell proliferation and migration, which is central to studying vascular development and disease. Cancer research depends heavily on VEGF165 for investigating tumor angiogenesis, one of the hallmarks of cancer progression. Regenerative medicine uses it for tissue engineering and wound healing applications. VEGF165 also shows up in IVD diagnostics as a reference material or assay component for detecting VEGF levels. This versatility makes it valuable for understanding complex biological processes and developing new therapies.
| Application Area | Key Function of VEGF165 | Example Use |
|---|---|---|
| Angiogenesis | Stimulates blood vessel formation | Endothelial cell assays |
| Cancer Research | Promotes tumor vascularization | Anti-angiogenic drug screening |
| Regenerative Medicine | Enhances tissue repair | Scaffold functionalization |
| IVD Diagnostics | Biomarker detection | ELISA kits for VEGF levels |
For further insights into immune co-stimulation, we recommend exploring our detailed analysis on 《Recombinant Human 4-1BBL: Unlocking Immune Co-stimulation for Advanced Therapies》.
Regulatory Considerations for Biopharmaceutical Recombinant Proteins
The regulatory landscape for biopharmaceutical recombinant proteins is complex to navigate. Regulatory compliance is non-negotiable for products intended for therapeutic or diagnostic use. We adhere to international standards such as ICH guidelines and relevant FDA guidelines. These frameworks set strict requirements for manufacturing, quality control, and documentation. Robust quality management systems run throughout our production process, ensuring traceability and batch-to-batch consistency. Understanding these regulatory pathways is fundamental for successful product development and market approval. Our commitment to these standards keeps our recombinant protein raw materials reliable and safe.
Future Directions and Innovations in VEGF165 Research
VEGF165 research continues to evolve in promising directions. Ongoing studies are exploring its potential in gene therapy for ischemic diseases, where delivering VEGF directly could promote revascularization. Drug discovery efforts keep producing novel inhibitors and activators targeting the VEGF pathway. Personalized medicine approaches aim to tailor VEGF-based therapies to individual patient profiles. VEGF165 also serves as a biomarker development tool for monitoring disease progression and treatment response. These innovations underscore why VEGF165 remains so important in advancing biomedical science. We support these advancements by providing high-quality recombinant protein raw materials.
Frequently Asked Questions About Recombinant Human VEGF165
What makes East-Mab’s Recombinant Human VEGF165 ideal for therapeutic research?
East-Mab’s Recombinant Human VEGF165 is produced under stringent quality controls, ensuring exceptionally high purity VEGF165 and biological activity. Our advanced production platform focuses on minimizing endotoxin levels and maximizing stability, making it well-suited for sensitive therapeutic research and biopharmaceutical applications where consistency and reliability are paramount. We prioritize critical quality attributes to support your most demanding projects.
How does the quality of Recombinant Human VEGF165 affect angiogenesis assays?
The quality of Recombinant Human VEGF165 directly impacts the accuracy and reproducibility of angiogenesis assays. High-purity, highly active VEGF165 ensures consistent cellular responses, such as endothelial cell proliferation, migration, and tube formation. Impurities or low activity can lead to unreliable data, compromising the validity of your angiogenesis research. East-Mab’s VEGF165 is validated for optimal performance in these assays.
Can Recombinant Human VEGF165 be customized for specific cell culture media formulations?
Yes, East-Mab offers flexibility in supporting specific requirements for Recombinant Human VEGF165. While our standard product meets broad industry needs, we understand that unique cell culture media formulations or specific research protocols may require tailored solutions. Our technical team can work with you to understand your needs and explore customization options to ensure optimal integration into your cell culture system.
What are the storage and handling recommendations for Recombinant Human VEGF165?
Proper storage and handling are key to maintaining the stability and biological activity of Recombinant Human VEGF165. Generally, it should be stored at -20°C to -80°C in aliquots to avoid repeated freeze-thaw cycles. Once reconstituted, it is typically stable for a limited period at 4°C. Always refer to the product-specific data sheet provided by East-Mab for detailed instructions on reconstitution, storage, and handling.
Partner with East-Mab Biomedical for Superior Recombinant Protein Solutions
Take your research and development further with high-quality Recombinant Human VEGF165 and other premium recombinant protein raw materials from Jiangsu East-Mab Biomedical Technology Co., Ltd. Backed by over $30 million in R&D investment and a commitment to global advancements in IVD, cell culture, and cell therapy, we provide the purity, activity, and reliability your applications demand. Contact our experts today to discuss your specific requirements and discover how East-Mab can support your next breakthrough. Reach us at +86-400-998-0106 or product@eastmab.com.